COMPANY PROFILE / #1168
Human Longevity
San Diego, CAVenture Capital-Backed
OVERVIEW
Developer of a biotechnology platform designed to combine genomic and phenotypic information to accelerate the understanding of human health. The company's platform addresses the age-related decline in endogenous stem cell function and concentrates on cancer, diabetes, obesity, heart and liver diseases, and dementia by combining deoxyribonucleic acid sequencing and expert analysis with machine learning, enabling people to shape their health and shift the practice of medicine from reactive to proactive technologies.
已融资1,072.80
最新估值250.00
员工数80
成立年份2013
公司概况
- Companies
- Human Longevity
- Description
- Developer of a biotechnology platform designed to combine genomic and phenotypic information to accelerate the understanding of human health. The company's platform addresses the age-related decline in endogenous stem cell function and concentrates on cancer, diabetes, obesity, heart and liver diseases, and dementia by combining deoxyribonucleic acid sequencing and expert analysis with machine learning, enabling people to shape their health and shift the practice of medicine from reactive to proactive technologies.
- Website
- www.humanlongevity.com
- HQ Location
- San Diego, CA
- Year Founded
- 2013
- Keywords
- biotechnology discovery, cancer risk assessment, genomics study, genomics test, health intelligence platform, healthcare technology, human health, longevity biotech, phenotypic information
- Competitors
- I-gene (Biotechnology), Omixy, Genuity Science, MapMyGenome India, OmeCare, Calimmune, Syapse, Tmunity, Xcelthera, Xcode Life, Ambry Genetics, AlloVir, Humacyte, Juvenescence, Ocata Therapeutics, Counsyl, Orbsen Therapeutics, AVM Biotechnology, BioCardia, Knome (US), Navigenics, Personalis, Ancestry, Lumigenix, Chrome Holding
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 1,072.80
- First Financing Date
- 01-Jan-2013
- First Financing Size
- 500.00
- First Financing Valuation
- —
- Last Financing Date
- —
- Last Financing Deal Type
- Secondary Transaction - Private
- Last Financing Size
- —
- Last Financing Valuation
- —
- Last Financing Status
- Completed
- Last Known Valuation
- 250.00
- Last Known Valuation Date
- 21-Aug-2024
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 329.49
- Valuation Estimate Growth Rate
- 31.79%
- Active Investors
- BroadOak Capital Partners, Celgene, Emerging Technology Partners (Venture Capital), G Vision Capital, Illumina, Oceanpine Healthcare Fund, Panacea Capital (California), Shin Ryoku Trust, Singularity (Educational and Training Services (B2C)), TVM Capital Healthcare Partners
- # Active Investors
- 10
- Acquirers
- —
团队与联系人
- Employees
- 80
- Employee Growth %
- -1.23%
- Employee History
- 2026: 80, 2025: 81, 2024: 88, 2023: 85, 2022: 77, 2021: 73, 2020: 111, 2019: 131 E, 2018: 150, 2017: 225 E, 2016: 300
- Primary Contact
- Craig Venter
- Primary Contact Title
- Co-Founder & Chief Executive Officer
- Primary Contact Email
- cventer@jcvi.org
- Primary Contact Phone
- +1 (858) 200-1890
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- 0.00%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 13
- Size Multiple
- 10.00x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 93
- Majestic Referring Domains
- 903
- SimilarWeb Unique Visitors
- 2,748
- SimilarWeb Unique Visitors Change
- 104
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 13%
- Success Probability Over Time – 3 Year
- 34%
- Success Probability Over Time – 5 Year
- 45%
记录来源：public.companies · 原始序号 #1168 · 所有字段均按数据库原值展示。